ʻO ka $3 ʻO ka hōʻailona Billion Biotech Fund: Kahi e kūpono ai nā mea hiki i ka Peptide Platform i ke Kapena Kapena Aʻe

Pane wikiwiki

ʻO ka $3 billion headline is a capital-markets event, not a peptide demand forecast. OrbiMed raised $3 billion in commitments across two new private equity funds…

He aha ka OrbiMed i hāpai maoli ai, a ke hoʻololi nei kahi waihona mālama ola olakino i ka noi peptide?

Kūʻai nui Polypeptide ʻO Peptidyl Transferase ʻAʻole ia, ʻaʻole pololei. ʻO ka waihona kālā he kaʻa mālama ola olakino, ʻaʻohe mea i loko o ka hoʻolaha i kapa ʻia nā peptides, conjugates a i ʻole ka mana hana. ʻO ka nui ka hōʻailona; ʻaʻole i hōʻike ʻia ka ʻāpana ʻāpana.

ʻO ka $3 ʻO ka hōʻailona Billion Biotech Fund: Kahi e kūpono ai nā mea hiki i ka Peptide Platform i ke Kapena Kapena Aʻe

ʻO ka nui kālā o OrbiMed ma ke kaʻa, US$bn ʻO ka nui kālā o OrbiMed ma ke kaʻa, US$bn, e like me ka manao mai ke kumu i oleloia. ʻO ka nui kālā o OrbiMed ma ke kaʻa, US$bn. ʻikepili pā hui: 2021: Nā Waiwai Pilikino 1.5, Hoa o Asia 0; 2022: Nā Waiwai Pilikino 1.86, Hoa o Asia 0; 2026: Nā Waiwai Pilikino 1.9, Hoa o Asia 0; 2021 (IV): Nā Waiwai Pilikino 0, Hoa o Asia 0.8; 2023 (V): Nā Waiwai Pilikino 0, Hoa o Asia 0.751; 2026 (VI): Nā Waiwai Pilikino 0, Nā Hoa o Asia 1. Source: BioSpace 2026-10-16. ʻO ka nui kālā o OrbiMed ma ke kaʻa, US$bn 0 0.5 1 1.5 2 Nā Waiwai Pilikino Hoa o Asia 1.5 0 2021 1.86 0 2022 1.9 0 2026 0 0.8 2021 (IV) 0 0.751 2023 (V) 0 1 2026 (VI) Puna: BioSpace (2026-10-16)

ʻO ke kumu hoʻohālikelike mai ka paʻi kālepa ma mua o ka hoʻokuʻu. ʻO ka uhi ʻana o FierceBiotech wehewehe ʻo Asia Partners VI ʻo ia ka waihona kālā ʻAsia nui loa a OrbiMed, kūʻē $751 miliona no Asia Partners V a $800 miliona no Asia Partners IV, a ʻike ʻia ka piʻi hou ʻana i ʻekolu mau makahiki ma hope o ka pau ʻana o nā mea hou. ʻO ka moʻolelo kālā o BioSpace hoʻokomo ʻo Private Investments X ma $1.9 piliona kūʻē $1.86 piliona ma 2022 a $1.5 piliona ma 2021.

ʻO nā kiko kikoʻī o ka hoʻokuʻu ʻana ma AI, "ka hoʻonui ʻana o nā ʻano hana therapeutic hou" a me ka puka ʻana o Kina ma ke ʻano he mana biotechnology, per ka hoolaha. Noho ʻo Peptides i loko o "nā ʻano hana lapaʻau hou,” akā, ʻo ia kā mākou heluhelu, ʻaʻole ka ʻōlelo a ka ʻoihana. ʻO ka hopena kūpono: e mālama i ka hoʻonui ʻana ma ke ʻano he hōʻailona liʻiliʻi e hiki ke hoʻokuʻu i nā pūlāwai mua, ʻaʻole ia he hōʻike no ke koi ʻana no kekahi kemika kikoʻī.

ʻO ka $3 ʻO ka hōʻailona Billion Biotech Fund: Kahi e kūpono ai nā mea hiki i ka Peptide Platform i ke Kapena Kapena Aʻe

ʻO nā mana peptide e paʻakikī maoli e hoʻopili, a he mau lawelawe waiwai?

ʻO ka hana paʻakikī, huikau, ʻO ka hōʻailona a me ka synthesis maʻamau hiki i kēlā me kēia ke koi i ka mākaukau kūikawā. ʻAʻole hoʻokumu ka hōʻiliʻili kālā i nā lawelawe e loaʻa nā kauoha a i ʻole e lilo i mea hoʻololi; e loiloi i ka hana i hōʻike ʻia no ka papahana i manaʻo ʻia.

ʻO nā hōʻike no nā kaʻina paʻakikī he mea maʻamau. I ka 2026 Nature Chemistry papa helu, 49.9% o 539 Ua hōʻike ʻia nā kaʻina SPPS curated i ka hui ʻana ma-resin (ʻO Tamás et al., Nature Chemistry). ʻO nā hualoaʻa wānana o ka haʻawina like ka helu haʻi nui: ua hōʻea koʻikoʻi nā kumu hoʻohālike ma muli o ke kaʻina 58 i 60% pololei, ʻoiai ua kiʻi ʻia nā mana o ke kaʻina shuffled 57.7%, ʻaʻole i ʻoi aku ka maikaʻi ma mua o ka manawa kūpono ma kēlā set. ʻO ia hoʻi, ʻAʻole hiki iā ʻoe ke nānā i kahi kaʻina i ka polokalamu a ʻike inā e kūkulu ʻia.

ʻO ka lōʻihi kekahi kumu pilikia synthesis, ʻaʻole ia he palena pau ʻole 50-60 koena. E noi i nā hōʻike pili kaʻina a me ka nui, me nā ala ala ʻē aʻe inā kūpono.

ʻO ka conjugation ka lua o ka ʻāpana lōʻihi, a ʻo ka ʻāpana conjugation o ke alakaʻi EMA e wehewehe i ke kumu. Pono ia i ka mana o ka peptide unconjugated manuahi a me ke ʻano manuahi o ka moiety conjugate, e like me ka PEG manuahi a i ʻole ka loulou, a mālama i ka di-PEGylation, multi-PEGylation a me ka PEGylation kikoʻī ʻole ma ke ʻano he pilikia hoʻomalu (EMA synthetic peptide alakaʻi). Hoʻohui ʻia ka loiloi hana PDC i nānā ʻia e nā hui like ʻole i ka lāʻau lapaʻau-a-peptide me nā uku ʻona nui e hoʻonui i ka helu pae a me ke kaumaha QC (Parang et al., Hoʻolālā lāʻau lapaʻau, Hoʻomohala a hoʻomaʻamaʻa). ʻAʻole wehewehe ka mea kūʻai aku i nā lawelawe conjugation peptide ma ke ʻano he papa kuhikuhi.

No ke aha e lilo ai ka hohonu analytical i ka moat lōʻihi i ka holomua ʻana o nā papahana?

No ka mea, ua neʻe ka pā hoʻoponopono, a ua neʻe ʻo ia i ka mana o ka haumia peptide-specific ma mua o ka liʻiliʻi-mole ʻO ka Peptide Synthesis paʻamau. ʻO ka hohonu analytical ka mea e hiki ai i kahi hoa hana ke hoʻomau i ka ʻikepili pale ma hope o kēlā neʻe.

ʻO ke alakaʻi alakaʻi EMA i mana i Iune 2026 kau i nā paepae: ʻO nā mea haumia pili peptide i hōʻike ʻia ma luna 0.1%, i ʻike ʻia ma luna 0.5% a kūpono ma luna 1.0%, a pili nā palena like i nā huahana i hoʻopau ʻia (EMA synthetic peptide alakaʻi). ʻO ke kūlana o ke alakaʻi e pili ana i ka hui ʻana i nā haumia hiki ke hoʻokaʻawale ʻia e like me ka hana: pūʻulu mua- a ʻaʻole ʻōlelo ʻia nā piʻi ma hope o ka eluting a ʻae ʻia i nā hihia kūpono loa.

ʻElua mau mea ma hope. Ka mua, ʻO ka loina ICH Q6B maʻamau e paʻa mau ana ka maʻemaʻe, a ʻo Q6B e hoʻokaʻawale loa i nā peptides synthetic mai kāna kiko (I Q6B). ʻO ka maʻemaʻe kahi helu i hana ʻia e kahi ʻano, aole he waiwai o ka hue. Ka lua, ua neʻe like ka ʻaoʻao US: ka FDA o Iulai 2026 hoʻoponopono hou i kāna alakaʻi peptide maʻamau i paʻi ʻia 17 hoʻoponopono hou ʻia nā kumu aʻoaʻo kikoʻī huahana e uhi ana i nā paepae haumia, ʻoihana kiʻekiʻe a me ka hana olaola, a ua hoʻihoʻi ka ʻoihana i kāna Mei 2021 alakaʻi ʻaʻole e hōʻike hou ana i ka noʻonoʻo ʻepekema o kēia manawa (U.S. FDA). Kūʻai Peptide

No laila ʻo Scalable peptide analytics kahi mea kikoʻī: nā ʻano orthogonal, hoʻoili palapala, a me nā kūlana kuhikuhi nona nā waiwai i hāʻawi ʻia e hiki ke ʻimi ʻia. He hana ʻelua ʻanuʻu ka hāʻawi waiwai maʻamau o ka USP, koena nui ma luna o nā mea nui a laila hoʻopaʻa i ka HPLC assay ma ka lyophilised vial, no ka mea, ke alakaʻi ʻia kahi maʻamau i kuhi hewa ʻia i ka dosing hewa (McCarthy et al., ʻImi Lapaʻau). E nīnau i kahi hoa pehea i hoʻonohonoho ʻia ai kā lākou mau kūlana ma mua o kou ʻae ʻana i kahi kiʻi maʻemaʻe.

He aha ka $1 ʻO ka hoʻokaʻawale ʻana o ʻAsia no ka hoʻoholo ʻana o ke alakaʻi CMC?

He mea maoli ka pōʻaiapili. Ua helu ʻia nā biotechs i hoʻokumu ʻia ma Kina 58% o na waiwai kuai laikini a pau ma 2026 i kēia lā kūʻē 26% no nā hui US, mai a 14% i 48% mokuahana 2023, per BioSpace, e kuhikuhi ana i ka ʻikepili ʻo Locust Walk. ʻO nā papa inoa kōpili o OrbiMed i kēia manawa 22 ʻO nā hui biopharma Asia (FierceBiotech). E mālama i ka helu laikini e like me ke kuhikuhi: hele mai ia mai kahi ʻoihana aʻoaʻo kālepa e pōmaikaʻi ana mai ka moʻolelo cross-border.

No kāu hoʻoholo hoʻoholo, ʻO nā kumu kūpono he palapala a me ka mana. E noi i nā ʻikepili kikoʻī like ʻole āu e makemake ai ma ka home, e hōʻoia i ka paena e hana i ka pae, a e hoʻopaʻa koke i ka neʻe ʻana o nā ʻano analytical i kāu lab ponoʻī. ʻO ka pilikia o nā kulekele e pili ana i ka lako ma Kina he ola, kumuhana i hoʻoholo ʻole ʻia; ʻaʻole mākou e kūkulu i kahi hoʻolālā kumu no ka hopena ʻahaʻōlelo i hoʻoholo ʻole ʻia.

Pehea wau e haʻi ai i ka waiwai paʻa paʻa mai ke kālā-cycle buzz ke loiloi au i kahi hoa peptide?

Kākoʻo ʻia kahi koi kūpono e nā kaʻina hana kūpono a me nā hōʻike analytical ma lalo o nā koina o ka papahana. ʻAʻole wānana ʻo Lot palapala wale nō inā e paʻa mau ka ʻoihana ʻoihana.

ʻAʻole i paʻi ʻia ka helu holomua mua no nā kaʻina paʻakikī, a ke kanalua nei makou i ka hai ana mai o kekahi. Aia ka holomua ma ke kaʻina, ʻoki ʻia ka unahi a me ka maʻemaʻe, no laila, ʻaʻole like ka pākēneka hoʻokahi ma nā papahana. E noi i nā hihia kumu.

ʻO kēia kahi kahi e hana ai nā MOL Changes: holo paʻa kā mākou hui, ʻāpana wai, hybrid a me ka inverse solid-phase synthesis me ka microbial fermentation, Hoʻohana i nā peptides cyclic a me nā glycopeptides, a hāʻawi i ka biotinylation a me ka lepili fluorescent, me HPLC, MS, pH, maʻiʻo, endotoxin a me ka sterility hoʻokolohua ma ke ʻano he ʻāpana o ka pūʻolo hoʻokuʻu. Hōʻike mākou i ka hāʻawi ʻana ma ke ʻano he mea hoʻopaneʻe i nā mea noiʻi ma o nā kaʻina lōʻihi ma mua o ka ʻōlelo ʻana i kahi lōʻihi loa, no ka mea, pili ke kaupaku kūpono i ke kaʻina. Inā ʻoe e loiloi ana i kahi hoa, e nīnau i kēlā me kēia moho i nā nīnau papa inoa ma luna a hoʻohālikelike i nā pane, ʻaʻole nā ​​brochures.

He aha ka mea i hōʻike ʻia e ka moʻolelo hana e pili ana i nā ala kemika versus recombinant?

ʻO ke koho ʻana i ke ala he hoʻoholo ʻenehana kikoʻī o ka papahana, a ʻo ka loiloi paʻi ʻia o nā koho hana ma hope o ka blockbuster peptide lāʻau lapaʻau e mālama i ia ala ma mua o ka makemake maʻamau.. Mea Hoʻolako Eptides ʻOi aku ka mana o ka synthesis ma kahi pōkole o ka mole a pono e hoʻololi; komo nā ala hui hou i kahi e hiki ʻole ai ka lōʻihi a me ka pelu ʻana i ka hui kemika.

Pono e ʻike ʻia ka palena hoʻoponopono no ka mea e hoʻoholo i ke alakaʻi e hoʻokele i kāu faila. Pili ka EMA i nā peptides synthetic a ʻaʻole pili i nā huahana biological a me biotechnological i hana ʻia e nā ʻenehana recombinant. (EMA synthetic peptide alakaʻi). Hōʻike ʻia nā peptides semi-synthetic a me recombinant i ka FDA 2026 nā hoʻoponopono alakaʻi ma ke ʻano he ʻano hoʻouna ʻokoʻa (U.S. FDA). No laila kāu koho ala e hoʻoholo ai i kāu mau manaʻolana analytical, ʻaʻole wale kāu hoʻolālā kumukūʻai.

Nīnau pinepine

E hoʻonui paha ka OrbiMed i ka mana peptide CDMO?

ʻAʻole ma kāna iho. Ua uhi ʻia ka mana o ka hoʻokuʻu ʻana i nā biopharmaceuticals, nā mea lapaʻau, diagnostics a me nā lawelawe mālama ola kino, a ʻaʻohe inoa hoʻopukapuka hana (ʻO OrbiMed). Pono nā hui peptide e hiki mai ana ma o nā hoʻoholo hoʻokaʻawale portfolio ʻaʻole i hōʻike ʻia. E hoʻolālā i ka mana ma nā ʻaelike hoʻolako i pūlima ʻia, ʻaʻole ma nā hoʻolaha kālā. Hale Hana Eptides

He aha nā paepae haumia e paʻa iaʻu i kahi mea hoʻolako peptide?

No ka waiho ʻana i ka EU, e hoʻohana i nā paepae EMA: hoike maluna 0.1%, hoʻomaopopo ma luna 0.5%, kūpono ma luna 1.0%, hoʻohana ʻia i ka huahana i hoʻopau ʻia a me ka mea lāʻau (EMA synthetic peptide alakaʻi). No ka waiho ʻana maʻamau o US, e nānā i ke alakaʻi kikoʻī o kēia huahana no kāu huahana kuhikuhi, mai ka lulai 2026 ua hoʻololi nā hoʻoponopono i kekahi mau manaʻo.

He lahilahi nā palapala a kaʻu hoa noho. Hiki ke hoʻololi ʻia nā ala waena o ka papahana?

ʻAe maʻamau, akā, ʻo ka hoʻoili ʻana iā ia iho ka pilikia, ʻaʻole kahi e hele ai. E noi i nā faila kumu kumu, ka pūʻolo hōʻoia a me nā moʻolelo haʻawina maʻamau ma mua o kou hana ʻana. ʻO kahi hoa hiki ʻole ke hana i kēlā mau mea ke haʻi nei iā ʻoe i kahi mea i hana ʻia ai ka ʻikepili.

Ka hopena

ʻO ka $3 ʻO ka piliona he hōʻailona waiwai, a ʻaʻole hiki i ka liquidity ke hoʻomau i ka hiki. He aha ka mea e paʻa ai ka mana o ka platform peptide ka hiki ke hana i ka ʻikepili pale i nā kaʻina paʻakikī a me nā conjugates hoʻomalu., ma lalo o nā paepae haumia i paʻa i loko 2026 a me nā manaʻolana analytical i hāpai ʻia e nā mea hoʻoponopono ʻEulopa a me US.

ʻO kā mākou manaʻo e hoʻōki i ka loiloi ʻana i nā hoa ma ka laulā o ka papa inoa a hoʻomaka e loiloi iā lākou ma nā hōʻike: he kaʻina paʻakikī like, he ala i kapa ʻia no ka hoʻomalu manuahi-linker, he maʻamau kuhikuhi hiki ke loaʻa, a me kahi moʻolelo hoʻonui i hoʻopaʻa ʻia. Inā ʻaʻole hiki i kahi hoa ke pane i kēlā mau nīnau ʻehā me nā moʻolelo kikoʻī nui, ʻaʻole pili ke koena o ka pitch.

E kamaʻilio me kahi loea loea e pili ana i kahi kaʻina paʻakikī a i ʻole kahi papahana hoʻonui, a lawe mai i ke kaʻina āu e hopohopo nei.

Hōʻike: Hāʻawi ʻo MOL Changes i ka synthesis peptide maʻamau, hoʻololi, lepili a me nā lawelawe hoʻāʻo analytical. Ua kākau ʻia kēia ʻatikala e kā mākou hui no ka poʻe heluhelu e loiloi ana i nā hoa peptide a ʻaʻole ia he ʻōlelo aʻoaʻo hoʻoponopono.

Hōʻike ka mea hoʻopuka: Hāʻawi ʻo MOL Changes i nā lawelawe peptide a he hoihoi koʻikoʻi i kēia kumuhana. ʻO nā lālā lawelawe a me nā ʻōlelo hiki ke koi i nā mea hoʻolako; ʻO ka loaʻa a me ka hana ʻana no kahi kūkulu kikoʻī e koi i nā hōʻike kikoʻī o ka papahana.

Miao He

Miao He

ʻepekema noiʻi ma nā ʻōnaehana hoʻouna Kaʻike kumu: Hāʻawi peptide waha, lipid nanoparticle (LNP) hoʻopili ʻana, nā peptides komo i loko o ke kelepona (CPPs), a me nā hoʻopuka hoʻokuʻu mau.

Pilikino: ʻO nā luʻi nui i ka hoʻomohala ʻana i nā lāʻau peptide aia i loko o ko lākou mau hapalua ola pōkole a paʻakikī me ka hoʻokele waha, a ʻo Miao ʻO ia kekahi loea alakaʻi i ka hoʻoponopono ʻana i kēia mau pilikia. Loaʻa iā ia ka ʻike nui ma ke kahua o nā ʻōnaehana lawe peptide. Ke hoʻomau nei ʻo ia i ka hoʻomohala ʻana i nā mea hoʻonui permeation novel a me nā nanospheres e hoʻomaikaʻi nui i ka bioavailability o peptides..

ʻIke ʻia & Nā alakaʻi hoʻoponopono
Nānā ʻia e: Ka poe akamai kumuhana
Kaʻana like i kēia ʻatikala
Home Huli Whatsapp Nā lawelawe Huahana